Citations

Clear

362 citation(s) found for "Shaw, D A".

Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Yaghi, Shadi, Shu, Liqi , Mandel, Daniel , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Seiffge, David , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Mena, Diego López, Araúz, Antonio , Nehme, Ahmad , Boulanger, Marion , Sousa, João André , Sargento‐Freitas, João , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Kaufmann, Josefin E. , Engelter, Stefan T. , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Metanis, Issa , Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , MacDonald, Jason , Shahripour, Reza Bavarsad , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim, Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Giles, James , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Chulluncuy‐Rivas, Roberto, Aziz, Yasmin , Bakradze, Ekaterina , Tran, Thanh Lam , Rodrigo‐Gisbert, Marc , Velez, Faddi Saleh, Gracia, Jorge Ortiz, Mudassani, Varsha, Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Ranasinghe, Tamra , Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel, Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Lingam, Sivani, Quereshi, Abid, Alvarado, Alonso, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris, Vasilis, Martínez-Marino, Manuel , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Kala, Narendra , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Alvarado‐Bolaños, Alonso , Tentolouris-Piperas, Vasileios , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Liebeskind, David S. , Field, Thalia S , Keser, Zafer , Aziz, Yasmin , Mandel, Daniel M , Seiffge, David , Arauz, Antonio , Sousa, Joao Andre , Sargento-Freitas, Joao , Castro-Chaves, Paulo , Kaufman, Josefin E , Engelter, Stefan T , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Nolte, Christian H , Bavarsad Shahripour, Reza , Almajali, Mohammad , Fonseca, Ana Catarina , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Nzwalo, Hipolito , Mac Grory, Brian , Eltatawy, Ali , Rodrigo Gisbert, Marc , Vishnu, Venugopalan Y , Ranasinghe, Tamra , Mendes Ferreira, Vítor , Kim, Young Dae , Elangovan, Cheran , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Ghani, Mohammad , Xiao, Han , Khan, Farhan , Nehme, Ahmad , Yaghi, Shadi , Antonenko, Kateryna , Arnold, Marcel , Touzé, Emmanuel , Leker, Ronen R , Burton, Tina , von Rennenberg, Regina , MacDonald, Jason, Guo, Xiaofan , Samaniego, Edgar A , Rioux, Bastien , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Zedde, Marialuisa , Pascarella, Rosario , Anadani, Mohammad , Kicielinski, Kimberly , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Siegler, James E. , Willey, Joshua , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Martins, Sheila , Fridman, Sebastian , Liu, Shilin , Ali, Farman, Morsi, Rami Z. , Sokhi, Dilraj , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Stretz, Christoph , Goldstein, Eric

Mayo Clinic

Stroke | June 4, 2025 | Volume: 55 | Issue: 4 | Pages: 908-918

10.1161/strokeaha.123.045731 | PMID 38335240 Get It

BACKGROUND: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation. METHODS: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments. RESULTS: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45–1.12]; P =0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28–2.24]; P =0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35–5.45]; P =0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53–20.13]; P =0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18–0.88]; P interaction =0.009). CONCLUSIONS: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
A Unique Approach to Interdisciplinary Programmatic Palliative Care Development: Extending Into the Realm of Pediatric Palliative Oncology
Uber, Allison, Adams, Roberta H. , Marcus, Shannon, Otto, Mario , Shaw, Tressia, Cuviello, Andrea

Mayo Clinic

Pediatric Blood & Cancer | June 3, 2025 | Volume: 72 | Issue: 8 | Pages: No page available

10.1002/pbc.31839 | PMID 40457552 Get It

ABSTRACTBarriers to pediatric palliative care (PPC) integration in pediatric oncology encompass resource availability, provider attitudes, patient/family hesitancy, and timing. We report on a unique multistep approach for the creation of a pediatric palliative oncology program that (1) optimizes PPC delivery for all resource‐typed settings, (2) offers continuity of care by spanning inpatient and outpatient clinical settings, (3) improves PPC equity through standardized referral practices, and (4) promotes collaborator buy‐in and partnership through the utilization of tools to introduce PPC to patients/families. Our model demonstrates success through objective increases in PPC consultation and reported satisfaction from patients, families, and oncologists.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Babiker, Hani M. , Picozzi, Vincent J. , Chandana, Sreenivasa R , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gállego, Javier , Bullock, Andrea J. , Chunyi, Hao, Hitre, Erika, Osipov, Arsen , Alés, Inmaculada, Dragovich, Tomislav, Lee, Woo Jin , Feeney, Kynan, Ueno, Makoto , Seufferlein, Thomas , Investigators, on behalf of the PANOVA-3 Study, Osipov, Arsen, Matrana, Marc , Blondin, Nicholas, Shroff, Rachna T. , Orr, Douglas, Anderson, Michael J. , Shields, Anthony F. , Hamm, John , Bullock, Andrea, Nagireddy, Sumana, Kolodney, Joanna, Dragovich, Tomislav, Maniam, Ajit, Sears, Judith D., Stilwill, Joseph, Cusnir, Mike , Niewiaroska, Anna, Small, William, Kasi, Anup, Tache, Jason, Ross, Sharona, Shihabi, Samer, Gandhi, Sunil, Reeves, J. N. , Green, Garrett , Feinstein, Trevor, Huyck, Timothy K., Ramdin, Nadia, Marsh, Robert , Jiang, Yixing , Hatoum, Hassan , Manda, Sudhir, Kochenderfer, Mark D., Illum, Henrik, Richards, Donald , Valilis, P., Wong, Lucas, Newton, Herbert B. , Abdelrahim, Maen, Einspahr, David, Siegel, Richard, McKenney, Scott, Narang, Mohit , Cárdenes, Higinia R. , Thanikachalam, Kannan , Raff, Joshua P. , Ye, Joseph , Behl, Deepti , Kam, Audrey E., DeRose, Paul, Tasneem, A. , Brenner, Warren, Santos, Jennifer De Los , Rausch, D C, Trikha, Gaurav, Gabrail, Nashat , Mowat, Rex B., Jahangir, Khawaja, Schumaker, Robert P. , Soffen, Edward , Bravin, Eric, Gupta, Mukul Kumar , Bedoya-Apraez, Ivan Dario, Kang, Tyler Y., Lemay, Frédéric , Vincent, Mark , Létourneau, Richard, Doehring, Christine, Haberkorn, Mike, Rußwurm, Karen, Chater, Jack, Küng, Marc , Schacher, Sabine, Passhak, Maria , Geva, Ravit , Hubert, Ayala, Golan, Talia , Senellart, Hélène, Trouilloud, Isabelle , Blan, Jean-Frederic, Dourthe, Luis-Marie, Roy, Florence Le, Martin-Babau, J., Greil, Richard , Schreil, Georg, Gerger, Armin , Eisterer, Wolfgang , Mercadé, T. Macarulla, Cubillo, Antonio , Pons, Francesc Valladares, Díaz, Inmaculada Alés, Rivera, Fernando , Sarvise, Mariano Ponz, Airoldi, Mario , Bellotti, Giovanna, Corsi, Domenico , Antonuzzo, Lorenzo , Melichar, Bohuslav, Holečková, Petra , Kotasek, Rostislav, Němeček, Radim , Cutsem, Eric van, Laethem, Jean‐Luc Van , Sym, Sun Jin , Kim, Jin Young , Oh, Sang Cheul , Park, Joon Oh, Kim, Jin Won , Lee, Myung Ah , Choi, Hye Jin, Kang, Seok Yun , Mruk, Andrzej, Freier, Beata, Kosakowska, Ewa Anna, Kocsis, Judit, Csőszi, Tibor , Hitre, Erika, Al-Farhat, Yousuf, Cang, Shundong , Jin, Gang , Zuo, Changzeng, Song, Lijie, Wu, Zheng , Gao, Jie , Zhang, Tao� , Wang, Yusheng , Yuan, Xin , Li, Zhi-Hua , Chen, Rufu , Cai, Xiujun , Zhu, Zhizhen, Bai, Yuxian , Bai, Chunmei, Yau, Thomas, Joubert, Warren , Wong, Ka Yeung Mark, Harris, Marion , Mišir, Ana, Faccio, Adilson , Cruz, Felipe Melo , Azevedo, Srergio De, Victorino, Ana Paula , Paiva, Tadeu Ferreira, Franke, Fábio , Tiscoski, Katsuki Arima , Parolla, Gabriel, Lilno, Flora, Siqueira, Mariana Bruno , Lyra, Marcos, Lira, Jose Luis Martinez, Oliva, Dolores Mendoza, Vazquez, Arturo, Luviano, Jesus Elvis Cabrera, Gutiérrez, Erika Castillo , Camargo, Vanessa Rosas, Guerra, Cristian Chavez, Flores, Osvaldo Hernandez, Contreras, Jessica Reyes, Villanueva, Ángel Gómez, Villanueva, Omar Zayas, Bullock, Andrea , Wyrwicz, Lucjan , Osipov, Arsen , De La Fouchardiere, Christelle , Lee, Woojin , Ueno, Makoto , Van Cutsem, Eric , Macarulla, Teresa , Babiker, Hani , Antonuzzo, Lorenzo , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gallego, Javier , Hitre, Erika, Fouchardière, Christelle de la , Dragovich, Tomislav, Philip, Philip A. , Cutsem, Eric Van , Macarulla, Teresa , Investigators, on behalf of the PANOVA-3 Study, Spigel, David R. , Osipov, Arsen, Lou, Emil , Bullock, Andrea, Dragovich, Tomislav, Coveler, Andrew L. , Arena, Francis P. , Kasi, Anup, Ross, Sharona , Reeves, James, Green, Garrett, Uemura, Marc Isamu , Ye, Joseph, Wang, James Z. , Rausch, Daniel, Park, Jae‐Hyun , Schumaker, Robert, Gupta, Mukul, Letourneau, Richard, Fuchs, Martin , Vogel, Arndt , Chater, Jack, Schacher, Sabine, Stemmer, Salomon M. , Dourthe, Luis-Marie, Abdelghani, Méher Ben , Pons, Francesc Valladares, Guillén‐Ponce, Carmen , Yayá, Ricardo , Ponz‐Sarvisé, Mariano , Vincenzi, Bruno , Melichar, Bohuslav, Petruzelka, Lubos B. , Cutsem, Eric van, Borbath, Ivan , Hwang, Jun‐Eul , Oh, Sung Yong , Lee, Moon Hee , Choi, Hye Jin , Chon, Hong Jae , Ramlau, Rodryg , Mruk, Andrzej, Hitre, Erika, Bassam, Ali, Hao, Chunyi , Liang, Bo , Li, Wei , Bai, Chunmei , Joubert, Warren, Marx, Gavin M. , Azevedo, Srergio De, Hoff, Paulo M. , Vazquez, Arturo, Guerra, Cristian Chavez, Cortez, David Orta, Campos-Gómez, Saúl , Espinoza, Iván Romarico González

Mayo Clinic

Journal of Clinical Oncology | May 31, 2025 | Volume: 43 | Issue: 21 | Pages: 2350-2360

10.1200/jco-25-00746 | PMID 40448572 Get It

PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with unresectable locally advanced pancreatic adenocarcinoma (LA-PAC). METHODS In this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 by intravenous infusion once a day on days 1, 8, and 15 of a 28-day cycle with or without TTFields. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), local PFS, pain-free survival, and overall response rate (ORR). Distant PFS was analyzed post hoc. RESULTS OS was significantly prolonged using TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel (median, 16.2 months [95% CI, 15.0 to 18.0] v 14.2 months [95% CI, 12.8 to 15.4]; hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.99]; P = .039). PFS, local PFS, and ORR were not improved. Pain-free survival was significantly prolonged with TTFields with gemcitabine/nab-paclitaxel (median, 15.2 months [95% CI, 10.3 to 22.8] v 9.1 months [95% CI, 7.4 to 12.7]; HR, 0.74 [95% CI, 0.56 to 0.97]; P = .027), as was distant PFS (median, 13.9 months [95% CI, 12.2 to 16.8] v 11.5 months [95% CI, 10.4 to 12.9]; HR, 0.74 [95% CI, 0.57 to 0.96]; P = .022). Device-related skin adverse events (AEs) were experienced by 76.3% of patients. Most device-related skin AEs were mild to moderate, with 7.7% of patients reporting a grade 3 AE. CONCLUSION This study demonstrated significant OS, pain-free survival, and distant PFS benefits for TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in patients with unresectable LA-PAC, with no additive systemic toxicity.
Delphi Panel for the Development of Diagnostic Criteria for Metastatic Cutaneous Crohn Disease
Ebriani, Joseph, Santiago-Soltero, Karla , Anshelevich, Ellen, Shields, Bridget E. , Charrow, Alexandra , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Burgin, Susan , Cices, Ahuva , Coromilas, Alexandra, Rosenbach, Misha , Shaw, Katharina S. , Watson, Alice J., Ebriani, Joseph , Dalal, Rahul S. , Panel, The Metastatic Cutaneous Crohn’s Disease Delphi, Agrawal, Manasi , Alavi, Afsáneh , Cowen, Edward W , Goldfarb, Noah , Hsiao, Jennifer L. , McGee, Jean S. , Ortega‐Loayza, Alex G. , Porter, Martina Lee , Wanat, Karolyn A. , Wong, Serre-Yu

Mayo Clinic

JAMA Dermatology | May 7, 2025 | Volume: 161 | Issue: 6 | Pages: 642

10.1001/jamadermatol.2025.1115 | PMID 40332924 Get It

ImportanceMetastatic cutaneous Crohn disease (MCD) is a rare condition for which there are currently no published diagnostic criteria. Formal MCD diagnostic criteria will expand clinical care and research by enabling future diagnostic code validation, crystallizing a more uniform disease entity for the purposes of translational research, and allowing the development of more formalized outcome measures aimed at treatment response.ObjectiveTo define a set of criteria for the diagnosis of MCD.Evidence ReviewIn this consensus statement, a panel of experts on MCD and related conditions was assembled. Their opinions were gathered regarding the clinical and histologic findings that are sufficient, necessary, and highly suggestive of MCD through serial survey. Subsequent surveys were continued until consensus was achieved. Sufficient was defined as a feature that, if noted, would enable diagnosis of MCD without any other signs, symptoms, or testing. Necessary was defined as a feature that must be present to establish a diagnosis of MCD. Highly suggestive referred to any other features that were indicative of MCD but did not qualify as sufficient or necessary to diagnose MCD.FindingsOf 24 experts invited, 19 agreed to participate, with a 79% to 100% response rate across 5 rounds conducted. Five patients were also invited to participate, but none opted to participate, citing lack of clinical expertise and time concerns. The experts were all from the US; 5 (26%) have practiced medicine for 0 to 5 years, 5 (26%) practiced for 6 to 10 years, 6 (32%) practiced for 11 to 15 years, and 3 (16%) practiced for more than 20 years. A total of 18 experts (95%) worked in an academic practice setting. There was consensus agreement that MCD could present as oral disease, genital disease, or, rarely, in another location. Consensus was achieved on 2 major and 5 minor criteria for genital/other subtypes of MCD and 5 minor criteria for oral MCD. There was consensus that, while there are some pathological findings that are highly suggestive of MCD, histologic criteria are not necessary for diagnosis.Conclusions and RelevanceA panel of experts reached consensus on the diagnostic criteria for MCD described in this study. These criteria include major and minor clinical criteria, along with histopathological criteria for the diagnosis of genital and oral MCD. This consensus is a crucial step in the diagnosis of and future treatment development for MCD, a rare and clinically understudied condition.
Abstract 7237: Rapid-onset squamous cell carcinoma and spontaneous regression following papillomavirus infection
Bilger, Andrea , Ward-Shaw, Ella , Lee, Denis L. , Chiang, Cheng-Ming, Buehler, Darya, King, Renee E. , Wu, Szu‐Yuan , Newton, Michael A. , Matkowskyj, Kristina A. , Sundberg, John P. , Hu, Rong , Lambert, Paul F.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7237-7237

10.1158/1538-7445.am2025-7237 Get It

Abstract Squamous cell carcinoma (SCC) development in mammals is thought to require months or years from the time that initial changes occur. We show that SCCs induced by the mouse papillomavirus MmuPV1, which are generally diagnosed 4-6 months post infection, can be found as soon as 2 weeks post infection. SCCs developed within 2 weeks in immune-competent, adult FVB (FVB/NTac) mice at sites prone to human papillomavirus (HPV)-induced tumors and cancers in human patients: the base of the tongue, the anus, and the skin. The anterior tongue, less susceptible than the base of the tongue to HPV-induced cancer in humans, was resistant to rapid-onset cancer. The presence of invasive cancer in histological tissue sections was verified by multiple pathologists. These diagnoses were corroborated by the results of a classic test of malignancy: skin tumors obtained two weeks post infection grew ectopically as subcutaneous grafts in immune-deficient hosts. Preventative treatment with a novel BRD4 inhibitor dramatically reduced the frequency of ear skin SCCs present 2 weeks post infection and significantly reduced overall disease severity. Like many human papillomaviruses, MmuPV1 lacks an E5 gene. Expression of HPV16 E5 driven by the Keratin 14 promoter in FVB mice (FVB/NTac-Tg(KRT14-HPV16E5*)33Plam/Plam) significantly increased the frequency of rapid-onset invasive cancers caused by MmuPV1 at the base of the tongue and in the anus. In an E5-transgenic mouse with a persistent MmuPV1-induced ear skin lesion, we detected a lymph node metastasis at 38 weeks - further demonstrating a cancer phenotype. Cancers and less severe dysplasia induced by infection at the base of the tongue or the anus spontaneously regressed within 4 to 8 weeks of infection; however, ear lesions persisted. When CD4+ and CD8+ T cells were depleted, lesions at the base of the tongue and anus also persisted, indicating that spontaneous regression involves a T cell-mediated immune response. These results indicate that papillomavirus infection alone is sufficient to induce rapid onset of invasive cancer, and that persistence of disease depends on the tissue-specific immune microenvironment. Citation Format: Andrea Bilger, Ella T. Ward-Shaw, Denis L. Lee, Renee E. King, Shwu-Yuan Wu, Michael A. Newton, Cheng-Ming Chiang, Darya Buehler, Kristina Matkowskyj, John P. Sundberg, Rong Hu, Paul F. Lambert. Rapid-onset squamous cell carcinoma and spontaneous regression following papillomavirus infection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7237.
Abstract 2284: Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits
Roberts, Lewis R. , Hassan, Manal M. , Roberts, Lewis R , Han, Younghun , Shaw, Vikram R. , Byun, Jinyoung , Hatia, Rikita , McGlynn, Katherine A. , Amos, Christopher I.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2284-2284

10.1158/1538-7445.am2025-2284 Get It

Abstract Hepatocellular carcinoma (HCC) mortality is increasing globally, partly due to the growing prevalence of non-viral liver diseases. Genome-wide association studies (GWAS) have identified genetic variants associated with HCC development. Leveraging GWAS summary statistics and linkage disequilibrium score regression (LDSR), we investigated disease co-development with non-viral HCC to provide unique insights into HCC etiology and prioritize relationships for further causal inquiry. We utilized the LDSR statistical framework to estimate the genetic correlation and heritability between non-viral HCC with 923 epidemiologic, behavioral, and clinical traits from the United Kingdom Biobank (UKBB) cohort. We observed a SNP-array heritability (h2 obs) of 0.20 for non-viral HCC. Next, we estimated the pairwise genetic correlation between non-viral HCC and heritable (h2 obs > 0.02) UKBB traits, identifying significant positive genetic correlations between non-viral HCC and blood-based biomarkers of liver injury (ALT, GGT) and allostatic load (including glycated hemoglobin, blood pressure, and total albumin). We also identified a positive genetic correlation between non-viral HCC and diseases associated with metabolic dysfunction-associated steatotic liver disease (MASLD), including diabetes, hypertension, chronic ischemic heart disease, and others. Non-viral HCC was negatively associated with filtered coffee intake but positively associated with instant coffee intake. In addition, smoking behavior and the amount of alcohol consumption in the UKBB cohort showed a positive association with non-viral HCC. Our study provides an atlas of cross-trait genetic correlations in non-viral HCC. Taken together, our results demonstrate possible polygenic pleiotropy between non-viral HCC and different phenotypic traits. The results support further exploration of the predictive power of blood-based biomarkers and selected behaviors for inferring HCC development among non-viral individuals. Citation Format: Younghun Han, Vikram Shaw, Jinyoung Byun, Rikita Hatia, Katherine McGlynn, Lewis Roberts, Manal Hassan, Christopher I. Amos. Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2284.
The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation
Wang, Guoqiao , Li, Yan, Xiong, Chengjie , Cao, Yuchen , Blennow, Kaj, Dage, Jeffrey L. , Jack, Clifford R. , Shaw, Leslie M. , Initiative, the Alzheimer's Disease Neuroimaging, Bateman, Randall J., Wang, Guoqiao , Jack, Clifford R , Dage, Jeffrey L , Li, Yan , Xiong, Chengjie , Cao, Yuchen, Schindler, Suzanne E. , McDade, Eric , Blennow, Kaj , Hansson, Oskar , Teunissen, Charlotte E. , Zetterberg, Henrik , Ibanez, Laura , Timsina, Jigyasha , Cruchaga, Carlos , Initiative, the Alzheimer's Disease Neuroimaging, Bateman, Randall J.

Mayo Clinic

Alzheimer's & Dementia | April 16, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14587 | PMID 40235082 Get It

Abstract INTRODUCTION Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging. METHODS To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts. RESULTS CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more comparable than their original scales across various biomarkers. DISCUSSION The versatility of CentiMarkers makes it a valuable tool for standardized biomarker comparison in AD research, enabling informed cross‐study comparisons and contributing to accelerated therapeutic development. Adoption of the CentiMarker scale could enhance biomarker reporting and advance our understanding of AD. Highlights Comparing fluid biomarkers without appreciating their magnitude relative to the disease can be challenging. We propose a CentiMarker metric to standardize biomarker measures from normal (0) and nearly maximum abnormal AD (100) ranges. CentiMarkers make the treatment effect more comparable across various biomarkers than when using the original scales.
Approaches to Timescale Choice in Cognitive Aging Research and Potential Implications for Estimated Exposure Effects: Coordinated Analyses in 10 Cohorts of Older Adults
Hayes‐Larson, Eleanor , Andrews, Ryan M. , Kezios, Katrina , Bercu, Ariane, Rouanet, Anaïs , Helmer, Catherine , Crane, Paul K. , Klinedinst, Brandon S. , McEvoy, Linda K. , Weuve, Jennifer , Rajan, Kumar B. , Shaw, Crystal , Sims, Kendra D. , Therneau, Terry M. , Petersen, Ronald C., Bouteloup, Vincent , Gross, Alden L. , Albert, Marilyn, Morris, John C., Resnick, Susan M. , Turney, Indira C. , Vonk, Jet M. J. , Avila‐Rieger, Justina , Weigand, Alexandra J. , Chen, Ruijia , Wang, Jingxuan , Mayeda, Elizabeth Rose , Klinedinst, Brandon S , McEvoy, Linda K , Weuve, Jennifer , Mez, Jesse , Sims, Kendra D , Therneau, Terry , Albert, Marilyn S. , Masters, Colin L , Resnick, Susan M , Maruff, Paul , Manly, Jennifer J , Turney, Indira C , Vonk, Jet M J , Avila-Rieger, Justina , Weigand, Alexandra , Mayeda, Elizabeth Rose , Gibbons, Laura E. , Nichols, Emma , Rajan, Kumar Bharat , Hwang, Phillip H , Mez, Jesse , Farina, Mateo P. , Morris, John C. , Masters, Colin L. , Maruff, Paul , Manly, Jennifer J. , Proust‐Lima, Cécile

Mayo Clinic

Epidemiology | March 31, 2025 | Volume: 36 | Issue: 4 | Pages: 560-571

10.1097/ede.0000000000001859 | PMID 40164562 Get It

Background: Cognitive change is an important factor in understanding dementia. Estimating effects of exposures on cognitive change requires choosing an analytical timescale, typically time on study or current age. There is limited consensus regarding timescale choice in epidemiologic cognitive aging research. Methods: Using a coordinated analytic approach in 10 cohorts of older adults, we evaluated whether estimated effects of two exposures on memory change differed depending on timescale (time on study or current age). We modeled effects of apolipoprotein-E (APOE) ε4 genotype (a time-invariant exposure) and diabetes (a potentially time-varying/acquired exposure evaluated at baseline) using mixed-effects models with linear and nonlinear time specifications for both timescales. Results: Among APOE ε4 carriers, model-estimated memory scores at baseline (time on study timescale) or at each cohort’s median baseline age (current age timescale) were lower, and the average rate of decline was faster than among APOE ε4 noncarriers. Model-estimated memory scores at baseline or at median baseline age were generally similar across baseline diabetes status, with variability across cohorts in the diabetes-memory change association. In some cohorts, trends in diabetes-memory change associations differed in direction across timescales. Conclusions: Timescale was largely inconsequential for estimated effects of APOE genotype, but yielded differences in estimated diabetes effects, raising questions about the appropriate scale. The current age scale may be problematic because diabetes was measured heterogeneously in age across individuals, a common issue in aging cohorts. Our work demonstrates approaches to evaluate alternative timescales, including in multicohort analyses, and highlights potential implications for estimated exposure effects on cognitive change.
Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Mandel, Daniel , Shu, Liqi , Chang, Christopher , JACK, N , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Araúz, Antonio , Boulanger, Marion , Sousa, João André , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , Macdonald, J , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim J. , Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Rivas, Roberto Chulluncuy, Bakradze, Ekaterina , Tran, Thanh Lam , Ortiz-Garcia, Jorge , Muddasani, Varsha , Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel Paulo , Krishnaiah, Balaji , Lingam, Sivani, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris-Piperas, Vasileios , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Liu, Shilin, Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Mongare, Newnex, Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Mandel, Daniel M , Jack, Naomi , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Antonenko, Kateryna , Seiffge, David , Arnold, Marcel , Salehi Omran, Setareh , Crandall, Ross , Lopez Mena, Diego , Arauz, Antonio , Boulanger, Marion , Touzé, Emmanuel , Sousa, Joao Andre , Sargento-Freitas, Joao , Barata, Vasco , Castro-Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Rothstein, Aaron , Khazaal, Ossama , Kaufman, Josefin E , Engelter, Stefan T , Traenka, Christopher , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Zhou, Lily W , Gandhi, Preet , Field, Thalia S , Metanis, Issa , Leker, Ronen R , Dantu, Vishnu , Baumgartner, Karl , Burton, Tina , von Rennenberg, Regina , Nolte, Christian H , Choi, Richard , MacDonald, Jason , Bavarsad Shahripour, Reza , Guo, Xiaofan , Ghannam, Malik , Almajali, Mohammad , Samaniego, Edgar A , Sanchez, Sebastian , Rioux, Bastien , Poppe, Alexandre , Fonseca, Ana Catarina , Fortuna Baptista, Maria , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Zedde, Marialuisa , Pascarella, Rosario , Grisendi, Ilaria , Nzwalo, Hipolito , Liebeskind, David S. , Molaie, Amir , Kam, Wayneho , Mac Grory, Brian , Al Kasab, Sami , Anadani, Mohammad , Kicielinski, Kimberly , Eltatawy, Ali , Chervak, Lina , Aziz, Yasmin , Bakradze, Ekaterina , Rodrigo Gisbert, Marc , Requena, Manuel , Saleh Velez, Faddi , Garcia, Jorge Ortiz , Muddasani, Varsha , de Havenon, Adam H , Vishnu, Venugopalan Y , Adams, Latasha , Ranasinghe, Tamra , Penckofer, Mary , Siegler, James E , Mayer, Silvia , Willey, Joshua , Zubair, Adeel , Cheng, Yee Kuang , Sharma, Richa , Marto, João Pedro , Mendes Ferreira, Vítor , Klein, Piers , Nguyen, Thanh N , Asad, Syed Daniyal , Balabhadra, Anvesh , Martins, Sheila , Mantovani, Gabriel , Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Qureshi, Abid Y , Fridman, Sebastian , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria , Vassilopoulou, Sofia , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Carrasco Wall, Victor , Indraswari, Fransisca , El Jamal, Sleiman , Liu, Shilin , Sarvath, Mohammed , Morsi, Rami Z , Kass-Hout, Tareq , Shi, Feina , Zhang, Jinhua , Sokhi, Dilraj , Simpkins, Alexis N , Ghani, Mohammad , Elnazeir, Marwa , Xiao, Han , Khan, Farhan , Stretz, Christoph , Goldstein, Eric D , Furie, Karen L , Yaghi, Shadi , Seiffge, David , Nehme, Ahmad , Sargento‐Freitas, João , Kaufmann, Josefin E. , Engelter, Stefan T. , Metanis, Issa , Shahripour, Reza Bavarsad , Guo, Xiaofan , Keser, Zafer , Giles, James , Zedde, Marialuisa , Pascarella, Rosario , Aziz, Yasmin , Rodrigo‐Gisbert, Marc , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Ranasinghe, Tamra , Siegler, James E. , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Kim, Young Dae , Elangovan, Cheran , Alvarado‐Bolaños, Alonso , Martínez-Marino, Manuel , Ali, Farman, Morsi, Rami Z. , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Kala, Narendra , Stretz, Christoph , Goldstein, Eric , Yaghi, Shadi

Mayo Clinic

Stroke | March 27, 2025 | Volume: 56 | Issue: 6 | Pages: 1413-1421

10.1161/strokeaha.124.048215 | PMID 40143807 Get It

BACKGROUND: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. METHODS: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression. RESULTS: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61–33.13]; P =0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04–8.91]; P =0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65–26.58]; P <0.001), and occlusive dissection (aHR, 2.34 [95% CI, 1.03–5.34]; P =0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16–0.80]; P =0.01). CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.
Radiation treatment for thymoma in a dog
Hitt, Mark E., Shaw, D. P., Hogan, P. M., Lennon, Vanda A. , Amann, John F.

Mayo Clinic

Journal of the American Veterinary Medical Association | February 6, 2025 | Volume: 190 | Issue: 9 | Pages: 1187

10.2460/javma.1987.190.09.1187 Get It